INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY
发明人:
LEE, Won Sup,이원섭,KIM, In Hoo,김인후,LEE, Sang Jin,이상진
申请号：
KRKR2013/009264
公开号：
WO2014/062004A1
申请日:
2013.10.16
申请国别(地区):
WO
年份:
2014
代理人:
摘要：
The present invention relates to: a recombinant adenovirus a host cell into which the recombinant adenovirus is introduced a pharmaceutical composition comprising the recombinant adenovirus as an active ingredient for preventing or treating cancers and a method for treating cancers comprising the step of administering the pharmaceutical composition including the recombinant adenovirus as an active ingredient to a subject in need of treatment at a pharmaceutically effective amount, wherein, the recombinant adenovirus comprises a promoter, a ribozyme which is targeted to human telomerase reverse transcriptase (hTERT) mRNA, and a p53 gene in an adenovirus backbone of which E1 and E3 are deleted. The recombinant adenovirus of the present invention inhibits the activity of hTERT mRNA, which is specifically overexpressed in cancer cells, by cutting hTERT mRNA through a trans-splicing ribozyme, and simultaneously allows p53, which is a therapeutic gene, to be expressed. Thus it is confirmed that cancer cells are effectively killed using the recombinant adenovirus of the present invention. Particularly, it is confirmed that liver tissue-specific migration, particularly selective motility toward cancer cells, is improved. Thus, since the recombinant adenovirus of the present invention does not show cell cytotoxicity to normal cells for systemic administration by having improved selective motility, the present invention can be used as a gene therapeutic agent for hepatoma cancer or metastatic liver cancer.La présente invention concerne : un adénovirus recombiné une cellule hôte dans laquelle ladénovirus recombiné est introduit une composition pharmaceutique comprenant ladénovirus recombiné comme ingrédient actif pour la prévention ou le traitement de cancers et un procédé de traitement de cancers comprenant létape dadministration de la composition pharmaceutique comprenant ladénovirus recombiné comme ingrédient actif à un sujet nécessitant un traitement en une quantité pha
